U.S. life sciences oncology company CBT Pharmaceuticals Inc. has rebranded as Apollomics Inc. and secured $100 million in a Series B round.

The company secured the funds to accelerate the development of its immunotherapy and targeted cancer therapy programs globally and to boost its pipeline.

The round was led by principal investment firm CMB International.

U.S.-based investment firm OrbiMed Asia and several new backers also participated in the Series B round.